1,048 results on '"HEMORRHAGE"'
Search Results
2. Tranexamic Acid vs Adrenaline for Controlling Iatrogenic Bleeding During Flexible Bronchoscopy: A Double-Masked Randomized Controlled Trial.
- Author
-
Badovinac, Sonja, Glodić, Goran, Sabol, Ivan, Džubur, Feđa, Makek, Mateja Janković, Baričević, Denis, Koršić, Marta, Popović, Filip, Srdić, Dražena, and Samaržija, Miroslav
- Subjects
- *
ADRENALINE , *CLUSTER randomized controlled trials , *SIGMOIDOSCOPY , *BRONCHOSCOPY , *IATROGENIC diseases , *HEMORRHAGE , *VISUAL analog scale , *TRANEXAMIC acid , *BIMATOPROST - Abstract
Background: The most commonly used topical hemostatic agents during flexible bronchoscopy (FB) are cold saline and adrenaline. Data on use of other agents such as tranexamic acid (TXA) for this purpose are limited.Research Question: Is TXA effective and safe in controlling iatrogenic bleeding during FB compared with adrenaline?Study Design and Methods: We conducted a cluster-randomized, double-masked, single-center trial in a tertiary teaching hospital. Patients were randomized in weekly clusters to receive up to three applications of TXA (100 mg, 2 mL) or adrenaline (0.2 mg, 2 mL, 1:10000) after hemostasis failure after three applications of cold saline (4°C, 5 mL). Crossover was allowed (for up to three further applications) before proceeding with other interventions. Bleeding severity was graded by the bronchoscopist using a visual analog scale (VAS; 1 = very mild, 10 = severe).Results: A total of 2,033 FBs were performed and 130 patients were randomized successfully to adrenaline (n = 65) or TXA (n = 65), whereas 12 patients had to be excluded for protocol violations (two patients from the adrenaline arm and 10 patients from TXA arm). Bleeding was stopped in 83.1% of patients (54/65) in both groups (P = 1). The severity of bleeding and number of applications needed for bleeding control were similar in both groups (adrenaline: mean VAS score, 4.9 ± 1.3 [n = 1.8 ± 0.8]; TXA: mean VAS score, 5.3 ± 1.4 [n = 1.8 ± 0.8]). Both adrenaline and TXA were more successful in controlling moderate bleeding (86.7% and 88.7%, respectively) than severe bleeding (40% and 58.3%, respectively; P = .008 and P = .012, respectively) and required more applications for severe bleeding (3.0 ± 0 and 2.4 ± 0.5, respectively) than moderate bleeding (1.7 ± 0.8 and 1.7 ± 0.8, respectively) control (P = .006 and P = .002, respectively). We observed no drug-related adverse events in either group.Interpretation: We found no significant difference between adrenaline and TXA for controlling noncatastrophic iatrogenic endobronchial bleeding after cold saline failure, adding to the body of evidence that TXA can be used safely and effectively during FB.Trial Registry: ClinicalTrials.gov; No.: NCT04771923; URL: www.Clinicaltrials: gov. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
3. Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study.
- Author
-
Akulian, Jason, Bedawi, Eihab O., Abbas, Hawazin, Argento, Christine, Arnold, David T., Balwan, Akshu, Batra, Hitesh, Uribe Becerra, Juan Pablo, Belanger, Adam, Berger, Kristin, Burks, Allen Cole, Chang, Jiwoon, Chrissian, Ara A., DiBardino, David M., Fuentes, Xavier Fonseca, Gesthalter, Yaron B., Gilbert, Christopher R., Glisinski, Kristen, Godfrey, Mark, and Gorden, Jed A.
- Subjects
- *
FIBRINOLYTIC agents , *THROMBOLYTIC therapy , *TISSUE plasminogen activator , *DABIGATRAN , *COHORT analysis , *HEMORRHAGE - Abstract
Background: Combination intrapleural fibrinolytic and enzyme therapy (IET) has been established as a therapeutic option in pleural infection. Despite demonstrated efficacy, studies specifically designed and adequately powered to address complications are sparse. The safety profile, the effects of concurrent therapeutic anticoagulation, and the nature and extent of nonbleeding complications remain poorly defined.Research Question: What is the bleeding complication risk associated with IET use in pleural infection?Study Design and Methods: This was a multicenter, retrospective observational study conducted in 24 centers across the United States and the United Kingdom. Protocolized data collection for 1,851 patients treated with at least one dose of combination IET for pleural infection between January 2012 and May 2019 was undertaken. The primary outcome was the overall incidence of pleural bleeding defined using pre hoc criteria.Results: Overall, pleural bleeding occurred in 76 of 1,833 patients (4.1%; 95% CI, 3.0%-5.0%). Using a half-dose regimen (tissue plasminogen activator, 5 mg) did not change this risk significantly (6/172 [3.5%]; P = .68). Therapeutic anticoagulation alongside IET was associated with increased bleeding rates (19/197 [9.6%]) compared with temporarily withholding anticoagulation before administration of IET (3/118 [2.6%]; P = .017). As well as systemic anticoagulation, increasing RAPID score, elevated serum urea, and platelets of < 100 × 109/L were associated with a significant increase in bleeding risk. However, only RAPID score and use of systemic anticoagulation were independently predictive. Apart from pain, non-bleeding complications were rare.Interpretation: IET use in pleural infection confers a low overall bleeding risk. Increased rates of pleural bleeding are associated with concurrent use of anticoagulation but can be mitigated by withholding anticoagulation before IET. Concomitant administration of IET and therapeutic anticoagulation should be avoided. Parameters related to higher IET-related bleeding have been identified that may lead to altered risk thresholds for treatment. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
- Author
-
Planquette, Benjamin, Bertoletti, Laurent, Charles-Nelson, Anaïs, Laporte, Silvy, Grange, Claire, Mahé, Isabelle, Pernod, Gilles, Elias, Antoine, Couturaud, Francis, Falvo, Nicolas, Sevestre, Marie Antoinette, Ray, Valérie, Burnod, Alexis, Brebion, Nicolas, Roy, Pierre-Marie, Timar-David, Miruna, Aquilanti, Sandro, Constans, Joel, Bura-Rivière, Alessandra, and Brisot, Dominique
- Subjects
- *
RIVAROXABAN , *LOW-molecular-weight heparin , *THROMBOEMBOLISM , *DISEASE relapse , *PULMONARY embolism , *ENOXAPARIN , *RESEARCH , *VEINS , *CLINICAL trials , *RESEARCH methodology , *ANTICOAGULANTS , *EVALUATION research , *COMPARATIVE studies , *RANDOMIZED controlled trials , *TUMORS , *STATISTICAL sampling , *HEMORRHAGE , *DISEASE complications - Abstract
Background: Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.Research Question: Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE?Study Design and Methods: In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months.Results: Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, and 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (both the intention-to-treat and per-protocol populations: cumulative incidence, 6.4% vs 10.1%; subdistribution hazard ratio [SHR], 0.75; 95% CI, 0.21-2.66). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 1.4% vs 3.7%; SHR, 0.36; 95% CI, 0.04-3.43). Major or clinically relevant nonmajor bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 12.2% vs 9.8%; SHR, 1.27; 95% CI, 0.49-3.26). Overall, 19 patients (25.7%) and 20 patients (23.8%) died in the rivaroxaban and dalteparin groups, respectively (hazard ratio, 1.05; 95% CI, 0.56-1.97).Interpretation: In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for noninferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided.Trial Registry: ClinicalTrials.gov; No.: NCT02746185; URL: www.Clinicaltrials: gov. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
5. An Original Risk Score to Predict Early Major Bleeding in Acute Pulmonary Embolism: The Syncope, Anemia, Renal Dysfunction (PE-SARD) Bleeding Score.
- Author
-
Chopard, Romain, Piazza, Gregory, Falvo, Nicolas, Ecarnot, Fiona, Besutti, Mathieu, Capellier, Gilles, Schiele, François, Badoz, Marc, and Meneveau, Nicolas
- Subjects
- *
ANEMIA diagnosis , *HEMORRHAGE diagnosis , *SYNCOPE , *RESEARCH , *PULMONARY embolism , *KIDNEY failure , *THROMBOLYTIC therapy , *PROGNOSIS , *ACQUISITION of data , *EVALUATION research , *RISK assessment , *COMPARATIVE studies , *ANEMIA , *PERFUSION imaging , *HEMORRHAGE , *PERFUSION , *DISEASE complications ,RESEARCH evaluation - Abstract
Background: Improved prediction of the risk of early major bleeding in pulmonary embolism (PE) is needed to optimize acute management.Research Question: Does a simple scoring system predict early major bleeding in acute PE patients, identifying patients with either high or low probability of early major bleeding?Study Design and Methods: From a multicenter prospective registry including 2,754 patients, we performed post hoc multivariable logistic regression analysis to build a risk score to predict early (up to hospital discharge) major bleeding events. We validated the endpoint model internally, using bootstrapping in the derivation dataset by sampling with replacement for 500 iterations. Performances of this novel score were compared with that of the VTE-BLEED (Venous Thrombo-Embolism Bleed), RIETE (Registro informatizado de la enfermedad tromboembólica en España; Computerized Registry of Patients with Venous Thromboembolism), and BACS (Bleeding, Age, Cancer, and Syncope) models.Results: Multivariable regression identified three predictors for the occurrence of 82 major bleeds (3.0%; 95% CI, 2.39%-3.72%): Syncope (+1.5); Anemia, defined as hemoglobin <12 g/dL (+2.5); and Renal Dysfunction, defined as glomerular filtration rate <60 mL/min (+1 point) (SARD). The PE-SARD bleeding score was calculated by summing all the components. Overall, 52.2% (95% CI, 50.29%-54.11%) of patients were classified as low bleeding-risk (score, 0 point), 35.2% (95% CI, 33.39%-37.04%) intermediate-risk (score, 1-2.5 points), and 12.6% (95% CI, 9.30%-16.56%) high-risk (score >2.5 points). Observed bleeding rates increased with increasing risk group, from 0.97% (95% CI, 0.53%-1.62%) in the low-risk to 8.93% (95% CI, 6.15%-12.44%) in the high-risk group. C-index was 0.74 (95% CI, 0.73-0.76) and Brier score 0.028 in the derivation cohort. Similar values were calculated from internal bootstrapping. Performance of the PE-SARD score was better than that observed with the VTE-BLEED, RIETE, and BACS scores, leading to a high proportion of bleeding-risk reclassification in patients who bled and those who did not.Interpretation: The PE-SARD bleeding risk score is an original, user-friendly score to estimate risk of early major bleeding in patients with acute PE. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Safety of Thoracentesis and Tube Thoracostomy in Patients With Uncorrected Coagulopathy: A Systematic Review and Meta-analysis.
- Author
-
Fong, Clare, Tan, Colin Wei Chang, Tan, Drusilla Kai Yan, See, Kay Choong, Chang Tan, Colin Wei, and Yan Tan, Drusilla Kai
- Subjects
- *
HEMORRHAGE prevention , *META-analysis , *SYSTEMATIC reviews , *RISK assessment , *BLOOD coagulation disorders , *PLEURA diseases , *THORACOSTOMY , *HEMORRHAGE , *DISEASE complications - Abstract
Background: Thoracentesis and tube thoracostomy are common procedures with bleeding risks, but existing guidelines may be overly conservative. We reviewed the evidence on the safety of thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy.Research Question: Is it safe to perform thoracentesis and tube thoracostomy in patients with uncorrected coagulopathy?Study Design and Methods: This systematic review was performed according to the Preferred Reporting Items for Systematic Review and Meta-Analysis guidelines. PubMed and Embase were searched from inception through December 31, 2019. Included studies involved patients with uncorrected coagulopathy because of disease (eg, thrombocytopenia, liver cirrhosis, kidney failure) or drugs (eg, antiplatelets, anticoagulants). Relevant outcomes were major bleeding and mortality.Results: Eighteen studies (5,134 procedures) were included. Using random-effects meta-analysis, the pooled major bleeding and mortality rate was 0 (95% CI, 0%-1%). No publication bias was found. Excluding six studies that were in abstract form, meta-analysis of the remaining 12 full articles showed that the pooled major bleeding and mortality rate also was 0 (95% CI, 0%-2%). Subgroup analysis performed for patients with uncorrected coagulopathy resulting from disease or drugs showed similar results.Interpretation: Among patients with uncorrected coagulopathy who underwent thoracentesis or tube thoracostomy, major bleeding and mortality complications were uncommon. Our results suggest that in appropriately selected patients, thoracentesis or tube thoracostomy can be performed safely.Trial Registry: PROSPERO; No.: CRD42020152226; URL: www.crd.york.ac.uk/prospero/. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
7. Safety and Performance of Transbronchial Cryobiopsy for Parenchymal Lung Lesions.
- Author
-
Herth, Felix J., Mayer, Max, Thiboutot, Jeffrey, Kapp, Christopher M., Sun, Jiayuan, Zhang, Xiaoju, Herth, Jonas, Kontogianni, Konstantina, and Yarmus, Lonny
- Subjects
- *
SOLITARY pulmonary nodule , *BIOPSY , *LUNGS , *ENDOSCOPIC ultrasonography , *CRYOSURGERY , *LUNG tumors , *RETROSPECTIVE studies , *FLUOROSCOPY , *BRONCHOSCOPY , *HEMORRHAGE , *THORACOSTOMY , *PNEUMOTHORAX - Abstract
Background: Despite advances in technology, the bronchoscopic diagnosis of parenchymal pulmonary lesions (PPLs) remains difficult to achieve. Transbronchial lung cryobiopsy (TLCB) offers the potential for larger samples with improved diagnostic yield; however, a paucity of data exists describing its safety and usefulness for the diagnosis of PPL.Research Question: What is the safety profile of TLCB for PPL?Study Design and Methods: An observational, retrospective, multicenter cohort study enrolled patients without endobronchial disease undergoing TLCB of PPL from 2015 through 2019. All procedures were performed using both rigid and flexible bronchoscopy with a flexible cryoprobe. Complication rates, including bleeding and pneumothorax rates, were collected. Bleeding was graded on a scale from 0 (trace) to 4 (requiring surgical intervention) with a grade of ≥ 3 considered clinically significant. Pneumothorax, tube thoracostomy placement, diagnostic yield, and need for subsequent interventions were recorded.Results: One thousand twenty-four patients underwent TLCB. One hundred eighty-eight patients (18%) experienced bleeding; in 36 patients (3.5%), the bleeding was clinically significant. Sixty-eight patients (6.6%) demonstrated a pneumothorax and 64 patients (6.3%) required drainage with tube thoracostomy. All chest drains were removed within 4 days, and no cases of prolonged air leak occurred. A definitive diagnosis was achieved in 932 patients (91%). Adenocarcinoma (46%) and metastatic disease (21%) were the most common diagnoses.Interpretation: TLCB showed an acceptable safety profile and diagnostic yield for the evaluation of PPL in this large retrospective cohort. Prospective clinical trials are underway to validate these findings further. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
8. CT Findings and Patterns of e-Cigarette or Vaping Product Use-Associated Lung Injury: A Multicenter Cohort of 160 Cases.
- Author
-
Kligerman, Seth J., Kay, Fernando U., Raptis, Constantine A., Henry, Travis S., Sechrist, Jacob W., Walker, Christopher M., Vargas, Daniel, Filev, Peter D., Chung, Michael S., Digumarthy, Subba R., Ropp, Alan M., Mohammed, Tan-Lucien, Pope, Kristen W., Marquis, Kaitlin M., Chung, Jonathan H., Kanne, Jeffrey P., Raptis, Costantine A, and Vargas, Daniel B
- Subjects
- *
LUNG injuries , *NICOTINIC agonists , *CANNABIS (Genus) , *PSYCHIATRIC drugs , *NICOTINE , *COMPUTED tomography , *HEMORRHAGE , *ACUTE diseases - Abstract
Background: e-Cigarette or vaping-induced lung injury (EVALI) causes a spectrum of CT lung injury patterns. Relative frequencies and associations with vaping behavior are unknown.Research Question: What are the frequencies of imaging findings and CT patterns in EVALI and what is the relationship to vaping behavior?Study Design and Methods: CT scans of 160 subjects with EVALI from 15 institutions were retrospectively reviewed. CT findings and patterns were defined and agreed on via consensus. The parenchymal organizing pneumonia (OP) pattern was defined as regional or diffuse ground-glass opacity (GGO) ± consolidation without centrilobular nodules (CNs). An airway-centered OP pattern was defined as diffuse CNs with little or no GGO, whereas a mixed OP pattern was a combination of the two. Other patterns included diffuse alveolar damage (DAD), acute eosinophilic-like pneumonia, and pulmonary hemorrhage. Cases were classified as atypical if they did not fit into a pattern. Imaging findings, pattern frequencies, and injury severity were correlated with substance vaped (marijuana derives [tetrahydrocannabinol] [THC] only, nicotine derivates only, and both), vaping frequency, regional geography, and state recreational THC legality. One-way analysis of variance, χ2 test, and multivariable analyses were used for statistical analysis.Results: A total of 160 patients (79.4% men) with a mean age of 28.2 years (range, 15-68 years) with EVALI underwent CT scan. Seventy-seven (48.1%), 15 (9.4%), and 68 (42.5%) patients admitted to vaping THC, nicotine, or both, respectively. Common findings included diffuse or lower lobe GGO with subpleural (78.1%), lobular (59.4%), or peribronchovascular (PBV) sparing (40%). Septal thickening (50.6%), lymphadenopathy (63.1%), and CNs (36.3%) were common. PBV sparing was associated with younger age (P = .02). Of 160 subjects, 156 (97.5%) had one of six defined patterns. Parenchymal, airway-centered, and mixed OP patterns were seen in 89 (55.6%), 14 (8.8%), and 32 (20%) patients, respectively. Acute eosinophilic-like pneumonia (six of 160, 3.8%), DAD (nine of 160, 5.6%), pulmonary hemorrhage (six of 160, 3.8%), and atypical (four of 160, 2.5%) patterns were less common. Increased vaping frequency was associated with more severe injury (P = .008). Multivariable analysis showed a negative association between vaping for > 6 months and DAD pattern (P = .03). Two subjects (1.25%) with DAD pattern died. There was no relation between pattern and injury severity, geographic location, and state legality of recreational use of THC.Interpretation: EVALI typically causes an OP pattern but exists on a spectrum of acute lung injury. Vaping habits do not correlate with CT patterns except for negative correlation between vaping > 6 months and DAD pattern. PBV sparing, not previously described in acute lung injury, is a common finding. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
9. A CASE OF DIFFUSE ALVEOLAR HEMORRHAGE IN ANCA-NEGATIVE GLOMERONEPHRITIS.
- Author
-
SAFFARI, PARDIS and BUI, BRIAN
- Subjects
- *
HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
10. DON'T FORGET THE LUNGS: A CASE REPORT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME INDUCING PULMONARY AND DIFFUSE ALVEOLAR HEMORRHAGE.
- Author
-
PATEL, HIREN, PATEL, URVI, PATEL, ARPITA, SULLIVAN, ABIGAYLE R, DESAI, KUNAL, and SHAH, SAJJAD H
- Subjects
- *
HEMOLYTIC-uremic syndrome , *LUNGS , *HEMORRHAGE , *THROMBOTIC thrombocytopenic purpura - Published
- 2023
- Full Text
- View/download PDF
11. OUTCOMES OF PULMONARY HEMORRHAGE WITH HENOCH-SCHÖNLEIN PURPURA IN ADULTS: A CASE REPORT AND LITERATURE REVIEW.
- Author
-
MANJAPPACHAR, NIRMALA, BRAHMASHETTAR, VIJAYALAKSHMI, POUDEL, SUJAN, NATES, JOSEPH L, and MUGANLINSKAYA, NARGIZ
- Subjects
- *
LITERATURE reviews , *ADULTS , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
12. PERIOPERATIVE BRONCHOSCOPIC MANAGEMENT OF MASSIVE AIRWAY HEMORRHAGE AS A COMPLICATION OF PULMONARY ENDARTERECTOMY.
- Author
-
SIMOVIC, JURAJ and SHARMA, AARUSHI
- Subjects
- *
AIRWAY (Anatomy) , *HEMORRHAGE , *ENDARTERECTOMY - Published
- 2023
- Full Text
- View/download PDF
13. PRE-PROCEDURAL APPLICATION OF TOPICAL TRANEXAMIC ACID TO PREVENT BLEEDING COMPLICATIONS FROM MECHANICAL CORING OF TUMORS.
- Author
-
KO, JUSTINE, NUDANU, JASMINE, IZUKA, SHANNON, WONG, ASHLEIGH, FAZAL MEHMOOD, BILAL, RODRIGUEZ, ERNESTO, and HEGDE, PRAVACHAN
- Subjects
- *
TOPICAL drug administration , *HEMORRHAGE , *TRANEXAMIC acid , *TUMORS - Published
- 2023
- Full Text
- View/download PDF
14. PSEUDO-SUBARACHNOID HEMORRHAGE (PSAH) SIGN OCCURRING POST-CARDIOPULMONARY ARREST: A MARKER OF POOR PROGNOSTICATION.
- Author
-
MIR, MIKAEL, JAIN, SHIKA, HASSAN, ESRAA, B. JAMA, ABBAS, RAUF, IBTISAM, KORSAPATI, AISHWARYA R, BOIKE, SYDNEY, ATTALLAH, NOURA, MUKESH, SINDU, SILWAL, SWECHCHHA, BISTA, KARUNA, NANDI, LIA, SEETHARAM MEDA, NAMRATHA, EL LABBAN, MOHAMAD, DAS, SUBHRALEENA, WANG, HAN, JOHNSON, DAVID W, ANJ KHAN, SYED, and K. JAIN, NITESH
- Subjects
- *
HEMORRHAGE , *ARREST - Published
- 2023
- Full Text
- View/download PDF
15. INTERSTITIAL LUNG DISEASE AND DIFFUSE ALVEOLAR HEMORRHAGE IN THE PRESENCE OF FAM-TRASTUZUMAB DERUXTECAN-NXKI (ENHERTU) FOR STAGE IV BREAST CANCER.
- Author
-
ROMAN PEREZ, HECTOR I, SESEMANN, LAUREN, ZERO, NATALIA, CLARKE KREGOR, ALEXANDRIA, PARK, YOONHO, and COUGHLIN, COLIN
- Subjects
- *
METASTATIC breast cancer , *INTERSTITIAL lung diseases , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
16. DIFFUSE ALVEOLAR HEMORRHAGE: A RARE MANIFESTATION OF HIGH-OUTPUT HEART FAILURE.
- Author
-
WAJID, SUMBAL, FAIZ, MARIUM, FARRUKH, LARABE, ROSENBERG, LISA, JAVED, ARIFA, and SINGH, GURPREET
- Subjects
- *
HEMORRHAGE , *PULMONARY alveolar proteinosis - Published
- 2023
- Full Text
- View/download PDF
17. PULMONARY HEMORRHAGE INDUCED BY AMPHETAMINE USE: A RARE COMPLICATION.
- Author
-
DURDEVIC, MOMCILO, BANIULIS, DOVILE, GRUEN, DAVID, DURDEVIC, DRAGANA, BASTAKOTI, SUBASH, MORKEVICIUS, MATAS, SHAH, SYED J, MENDOZA-AYALA, RAUL, TANKOSIC, NIKOLA, and NAARAAYAN, ASHUTOSSH
- Subjects
- *
AMPHETAMINES , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
18. A RARE CAUSE OF A LARGE RETROPERITONEAL HEMORRHAGE: MIGRATED URETERAL DOUBLE-J STENT.
- Author
-
KANDAH, OMAR, DUFF, RICHARD F, and SHERERTZ, ROBERT
- Subjects
- *
SURGICAL stents , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
19. INVASIVE PULMONARY ASPERGILLOSIS MASQUERADED BY POSITIVE ANCA ANTIBODY AND DIFFUSE ALVEOLAR HEMORRHAGE.
- Author
-
BURAGAMADAGU, BHANUSOWMYA C, DEEPAK, VISHAL, VAIDYA, VINITA, and AL-JAROUSHI, HATIM S
- Subjects
- *
PULMONARY aspergillosis , *MASQUERADES , *HEMORRHAGE , *IMMUNOGLOBULINS - Published
- 2023
- Full Text
- View/download PDF
20. Giant Intrathoracic Mass in a Young Woman With Acute Kidney Injury.
- Author
-
Matyjek, Anna, Stanowska, Olga, Talarek, Lukasz, Wagrodzki, Michal, Olszewska, Katarzyna, Castaneda-Wysocka, Patricia, Owczarek, Joanna, Szolkowska, Malgorzata, Prochorec-Sobieszek, Monika, Rymarz, Aleksandra, and Niemczyk, Stanislaw
- Subjects
- *
ACUTE kidney failure , *YOUNG women , *COUGH , *HEMORRHAGE , *HEMOPTYSIS - Abstract
Case Presentation: A 35-year-old woman without past medical history sought treatment for fatigue and dry cough of 3 weeks' duration. Basic laboratory tests revealed severe anemia. She had no history of bleeding, hemoptysis, dyspnea, or fever. The patient was admitted for RBC transfusion and more extensive diagnostics. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
21. Epidemiology, Risk Factors, and Outcomes of Diffuse Alveolar Hemorrhage After Hematopoietic Stem Cell Transplantation.
- Author
-
Zhang, Zhenmei, Wang, Can, Peters, Steve G., Hogan, William J., Hashmi, Shahrukh K., Litzow, Mark R., Patnaik, Mrinal S., Niven, Alexander S., and Yadav, Hemang
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOSPITAL mortality , *INTERNATIONAL normalized ratio , *DIAGNOSIS , *HEMORRHAGE , *PLATELET count - Abstract
Background: Diffuse alveolar hemorrhage (DAH) is an uncommon complication of hematopoietic stem cell transplantation (HCT) that carries high morbidity and mortality. Limited contemporary data are available regarding the incidence, outcomes, and risk factors for DAH.Research Question: What are the incidence, outcomes, and risk factors for DAH developing after HCT?Methods: This was a single-center retrospective cohort study of patients who underwent HCT between January 1, 2005, and December 31, 2016. The incidence and outcomes of DAH development were evaluated. A multivariate logistic regression model was used to analyze differences between survivors and nonsurvivors.Results: Of 4,350 patients undergoing first-time HCT, DAH was diagnosed in 99 (2.3%). DAH was seen in 40 of 3,536 autologous HCT recipients (1.1%) and 59 of 814 allogeneic HCT recipients (7.2%). Mean age was 53 ± 13 years, and median time of DAH diagnosis was 126 days (interquartile range, 19-349 days) after HCT. In-hospital mortality and mortality 1 year after DAH diagnosis were 55.6% and 76.8%, respectively. DAH diagnosis more than 30 days after transplantation (OR, 7.06; 95% CI, 1.65-30.14), low platelet count (OR, 0.98; 95% CI, 0.96-1.0; P = .02), elevated international normalized ratio (INR; OR, 4.08; 95% CI, 0.64-25.88; P = .046) and need for invasive mechanical ventilation (OR, 8.18; 95% CI, 1.9-35.21) were associated with higher in-hospital mortality. Steroid treatment did not alter mortality (P = .80) or length of stay (P = .65). However, among those who received steroids, survival was higher in whose who received modest-dose steroids (< 250 mg methylprednisolone equivalent/d) compared with those who received high-dose steroids (≥ 250 mg methylprednisolone equivalent/d; OR, 0.21; 95% CI, 0.07-0.72).Interpretation: The mortality of DAH after HCT remains high, and DAH can occur long after transplantation. Later development of DAH (>30 days after HCT), need for invasive mechanical ventilation, thrombocytopenia, and elevated INR are all associated with worse outcomes. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
22. Antiplatelet Drugs and Risk of Bleeding After Bedside Pleural Procedures: A National Multicenter Cohort Study.
- Author
-
Dangers, Laurence, Giovannelli, Jonathan, Mangiapan, Gilles, Alves, Mikael, Bigé, Naïke, Messika, Jonathan, Morawiec, Elise, Neuville, Mathilde, Cracco, Christophe, Béduneau, Gaëtan, Terzi, Nicolas, Huet, Isabelle, Dhalluin, Xavier, Bautin, Nathalie, Quiot, Jean-Jacques, Appere-de Vecchi, Corinne, Similowski, Thomas, and Chenivesse, Cécile
- Subjects
- *
PLATELET aggregation inhibitors , *HEMORRHAGE , *COHORT analysis , *UNIVARIATE analysis , *TRACHEA intubation , *THERAPEUTIC embolization , *RELATIVE medical risk , *RESEARCH , *BIOPSY , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *CHEST tubes , *COMPARATIVE studies , *PLEURA diseases , *LONGITUDINAL method - Abstract
Background: The decision-making on antiplatelet drug withdrawal or continuation before performing a pleural procedure is based on the balance between the risk of bleeding associated with the antiplatelet therapy and the risk of arterial thrombosis due to its interruption. Knowledge on antiplatelet therapy-associated risk of bleeding after pleural procedures is lacking.Research Question: Is the risk of bleeding associated with antiplatelet drugs increased in patients undergoing pleural procedures?Study Design and Methods: We conducted a French multicenter cohort study in 19 centers. The main outcome was the occurrence of bleeding, defined as hematoma, hemoptysis, or hemothorax, during the 24 h following a pleural procedure. Serious bleeding events were defined as bleeding requiring blood transfusion, respiratory support, endotracheal intubation, embolization, or surgery, or as death.Results: A total of 1,124 patients was included (men, 66%; median age, 62.6 ± 27.7 years), of whom 182 were receiving antiplatelet therapy and 942 were not. Fifteen patients experienced a bleeding event, including eight serious bleeding events. The 24-h incidence of bleeding was 3.23% (95% CI, 1.08%-5.91%) in the antiplatelet group and 0.96% (95% CI, 0.43%-1.60%) in the control group. The occurrence of bleeding events was significantly associated with antiplatelet therapy in univariate analysis (OR, 3.44; 95% CI, 1.14-9.66; P = .021) and multivariate analysis (OR, 4.13; 95% CI, 1.01-17.03; P = .044) after adjusting for demographic data and the main risk factors for bleeding. Likewise, antiplatelet therapy was significantly associated with serious bleeding in univariate analysis (OR, 8.61; 95% CI, 2.09-42.3; P = .003) and multivariate analysis (OR, 7.27; 95% CI, 1.18-56.1; P = .032) after adjusting for the number of risk factors for bleeding.Interpretation: Antiplatelet therapy was associated with an increased risk of post-pleural procedure bleeding and serious bleeding. Future guidelines should take into account these results for patient safety. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
23. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis.
- Author
-
Jiménez, David, García-Sanchez, Aldara, Rali, Parth, Muriel, Alfonso, Bikdeli, Behnood, Ruiz-Artacho, Pedro, Le Mao, Raphael, Rodríguez, Carmen, Hunt, Beverley J., and Monreal, Manuel
- Subjects
- *
COVID-19 , *HOSPITAL patients , *PULMONARY embolism , *HEMORRHAGE , *DIAGNOSIS , *PUBLICATION bias - Abstract
Background: Individual studies have reported widely variable rates for VTE and bleeding among hospitalized patients with coronavirus disease 2019 (COVID-19).Research Question: What is the incidence of VTE and bleeding among hospitalized patients with COVID-19?Methods: In this systematic review and meta-analysis, 15 standard sources and COVID-19-specific sources were searched between January 1, 2020, and July 31, 2020, with no restriction according to language. Incidence estimates were pooled by using random effects meta-analyses. Heterogeneity was evaluated by using the I2 statistic, and publication bias was assessed by using the Begg and Egger tests.Results: The pooled incidence was 17.0% (95% CI, 13.4-20.9) for VTE, 12.1% (95% CI, 8.4-16.4) for DVT, 7.1% (95% CI, 5.3-9.1) for pulmonary embolism (PE), 7.8% (95% CI, 2.6-15.3) for bleeding, and 3.9% (95% CI, 1.2-7.9) for major bleeding. In subgroup meta-analyses, the incidence of VTE was higher when assessed according to screening (33.1% vs 9.8% by clinical diagnosis), among patients in the ICU (27.9% vs 7.1% in the ward), in prospective studies (25.5% vs 12.4% in retrospective studies), and with the inclusion of catheter-associated thrombosis/isolated distal DVTs and isolated subsegmental PEs. The highest pooled incidence estimate of bleeding was reported for patients receiving intermediate- or full-dose anticoagulation (21.4%) and the lowest in the only prospective study that assessed bleeding events (2.7%).Interpretation: Among hospitalized patients with COVID-19, the overall estimated pooled incidence of VTE was 17.0%, with higher rates with routine screening, inclusion of distal DVT, and subsegmental PE, in critically ill patients and in prospective studies. Bleeding events were observed in 7.8% of patients and were sensitive to use of escalated doses of anticoagulants and nature of data collection. Additional studies are required to ascertain the significance of various thrombotic events and to identify strategies to improve patient outcomes.Trial Registry: PROSPERO; No.: CRD42020198864; URL: https://www.crd.york.ac.uk/prospero/. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
24. Two Immunocompromised Patients With Diffuse Alveolar Hemorrhage as a Complication of Severe Coronavirus Disease 2019.
- Author
-
Löffler, Christian, Mahrhold, Juliane, Fogarassy, Peter, Beyer, Martin, and Hellmich, Bernhard
- Subjects
- *
COVID-19 , *IMMUNOCOMPROMISED patients , *VIRUS diseases , *SYMPTOMS , *HEMORRHAGE - Abstract
Diffuse alveolar hemorrhage (DAH) is a severe and potentially life-threatening disease manifestation. In addition to autoimmune diseases such as antineutrophil cytoplasmic antibody-associated vasculitis and anti-glomerular basement membrane syndrome, pulmonary viral infections are known to be culprits of DAH. Health-care providers worldwide in the coronavirus disease 2019 pandemic have been confronted with an unprecedented number of viral lung infections, with great variance in symptoms and severity. Hemoptysis, the key symptom of DAH, is a rare complication. We present two cases of immunocompromised patients with rapidly developing hypoxemic respiratory failure and evidence of DAH in the context of severe acute respiratory syndrome coronavirus 2 infection. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
25. Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study.
- Author
-
Beyer, Sebastian E., Shanafelt, Colby, Pinto, Duane S., Weinstein, Jeffrey L., Aronow, Herbert D., Weinberg, Ido, Yeh, Robert W., Secemsky, Eric A., and Carroll, Brett J.
- Subjects
- *
THROMBOLYTIC therapy , *PULMONARY embolism , *HOSPITAL mortality , *COHORT analysis , *CARDIAC arrest , *FIBRINOLYTIC agents , *LENGTH of stay in hospitals , *VASOCONSTRICTORS , *INTRAVENOUS therapy , *ULTRASONIC imaging , *CEREBRAL hemorrhage , *GASTROINTESTINAL hemorrhage , *PATIENT readmissions , *SWAN-Ganz catheterization , *TREATMENT effectiveness , *ARTIFICIAL respiration , *LONGITUDINAL method , *HEMORRHAGE - Abstract
Background: There are increased options to deliver thrombolytic treatment for acute, high-risk pulmonary embolism (PE). The goals of this study were to examine practice patterns of systemic thrombolysis and catheter-directed thrombolysis (CDT) and to compare outcomes following CDT with ultrasound facilitation (CDT-ultrasound) and CDT alone.Methods: The study analyzed adults aged > 18 years with hospitalizations associated with acute PE and thrombolysis in the 2016 Nationwide Readmissions Database. The study identified characteristics associated with the use of systemic thrombolysis and CDT. Comparisons of CDT-ultrasound vs CDT alone were then made by evaluating in-hospital events and readmissions. The primary outcomes were in-hospital mortality and 30-day readmission rates.Results: Among 5,436 hospitalizations, systemic thrombolysis was used more often (n = 3,376; 62.1%) than CDT (n = 2,060; 37.9%). Compared with CDT, systemic thrombolysis was used more frequently in patients with higher rates of vasopressor use (4.3% vs 1.0%), shock (15.8% vs. 6.9%), cardiac arrest (12.7% vs 3.4%), and mechanical ventilation (19.0% vs 5.9%). Among patients who underwent CDT, 417 (20.2%) received CDT-ultrasound, and 1,643 (79.8%) received CDT alone. Rates of bleeding events, vasopressor use, and mechanical ventilation were similar between therapeutic strategies. Following adjustment, in-hospital mortality (OR, 1.19; 95% CI, 0.63-2.26; P = .59) and 30-day readmission rates (OR, 0.75; 95% CI, 0.47-1.22; P = .25) were not significantly different between CDT-ultrasound and CDT alone.Conclusions: Systemic thrombolysis is used more often than CDT in patients with acute PE, in particular among those with a greater prevalence of high-risk features. Among patients treated with CDT, there were no differences in events between CDT-ultrasound and CDT alone. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
26. Extracorporeal Membrane Oxygenation for Severe ARDS Due to Immune Diffuse Alveolar Hemorrhage: A Retrospective Observational Study.
- Author
-
Seeliger, Benjamin, Stahl, Klaus, Schenk, Heiko, Schmidt, Julius J., Wiesner, Olaf, Welte, Tobias, Kuehn, Christian, Bauersachs, Johann, Hoeper, Marius M., and David, Sascha
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *ADULT respiratory distress syndrome , *ADULT respiratory distress syndrome treatment , *HEMORRHAGE complications , *ANTI-glomerular basement membrane disease , *LENGTH of stay in hospitals , *PULMONARY alveoli , *INTENSIVE care units , *RESEARCH , *LUNG diseases , *RESEARCH methodology , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *HOSPITAL mortality , *GRANULOMATOSIS with polyangiitis , *ARTIFICIAL respiration , *COMPARATIVE studies , *IMMUNOSUPPRESSIVE agents , *MYOSITIS , *VASCULITIS , *HEMORRHAGE , *DISEASE complications - Abstract
On ICU admission, the median Sequential Organ Failure Assessment score was 14 (IQR, 10-19) in patients receiving ECMO vs 12.5 (IQR, 11-13) in patients without ECMO support (P =.160). At ECMO implantation, all but one patient received invasive ventilation, and one patient received nasal high-flow oxygen. Intracranial hemorrhage occurred in four of 19 patients receiving ECMO (three cases were fatal) vs one of 10 patients without ECMO (P =.454). [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
27. Usefulness of Simplified Pulmonary Embolism Severity Index Score for Identification of Patients With Low-Risk Pulmonary Embolism and Active Cancer: From the COMMAND VTE Registry.
- Author
-
Yamashita, Yugo, Morimoto, Takeshi, Amano, Hidewo, Takase, Toru, Hiramori, Seiichi, Kim, Kitae, Oi, Maki, Akao, Masaharu, Kobayashi, Yohei, Toyofuku, Mamoru, Izumi, Toshiaki, Tada, Tomohisa, Chen, Po-Min, Murata, Koichiro, Tsuyuki, Yoshiaki, Nishimoto, Yuji, Saga, Syunsuke, Sasa, Tomoki, Sakamoto, Jiro, and Kinoshita, Minako
- Subjects
- *
PULMONARY embolism , *CLINICAL trial registries , *CANCER-related mortality , *CAUSES of death , *RESEARCH , *MORTALITY , *RESEARCH methodology , *ANTICOAGULANTS , *PROGNOSIS , *ACQUISITION of data , *EVALUATION research , *MEDICAL cooperation , *DISEASE relapse , *SEVERITY of illness index , *RISK assessment , *COMPARATIVE studies , *TUMORS , *HEMORRHAGE , *DISEASE complications - Abstract
Background: The simplified Pulmonary Embolism Severity Index (sPESI) score is a practical score for identification of patients with low-risk pulmonary embolism (PE), although it has not been applied in patients with active cancer. The current study aimed to evaluate the usefulness of the sPESI score in patients with PE and active cancer.Methods: The COMMAND VTE Registry is a multicenter registry enrolling consecutive patients with acute symptomatic VTE. The current study population consisted of 368 patients with PE and active cancer. The 30-day clinical outcomes were compared between patients with sPESI score = 1 and patients with sPESI scores ≥ 2.Results: Overall, 37 patients (10%) died during the 30 days after diagnosis. The cumulative 30-day incidences of mortality, and PE-related death, were lower in patients with sPESI score = 1 than in patients with sPESI scores ≥ 2 (6.3% vs 13.1%; log-rank P = .03; and 0.7% vs 3.9%; log-rank P = .046). Among patients with sPESI score = 1, the predominant cause of death was cancer. There were no significant differences in the cumulative 30-day incidence of recurrent VTE and major bleeding between the two groups (3.9% vs 5.6%; log-rank P = .46; and 6.4% vs 4.5%; log-rank P = .45).Conclusions: Among patients with PE and active cancer, patients with sPESI score = 1 had a lower 30-day mortality rate compared with patients with sPESI scores ≥ 2, and they showed very low PE-related mortality risk, although the overall mortality rate remained high because of cancer-related mortality. They also showed relatively high risks for recurrence and major bleeding, suggesting the need for careful follow-up.Trial Registry: UMIN Clinical Trials Registry; No.: UMIN000021132; URL: http://www.umin.ac.jp/ctr/index.htm. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
28. Better With Ultrasound: Arterial Line Placement.
- Author
-
Wang, Ann, Hendin, Ariel, Millington, Scott J., Koenig, Seth, Eisen, Lewis A., and Shiloh, Ariel L.
- Subjects
- *
ARTERIAL catheterization , *HEMODYNAMIC monitoring , *CRITICALLY ill , *BLOOD sampling , *ARTERIAL catheters , *CATHETERIZATION , *CENTRAL venous catheterization , *ATHEROEMBOLISM , *FEMORAL artery , *HEMORRHAGE , *INTRAVENOUS catheterization , *RETROPERITONEUM , *SURGICAL complications , *ULTRASONIC imaging , *FALSE aneurysms , *COMPUTER-assisted surgery , *RADIAL artery - Abstract
Arterial catheterization is frequently performed in ICUs to facilitate hemodynamic monitoring and frequent blood sampling. Overall, arterial catheterization has high success and low complication rates, but in patients who are critically ill, the incidence of failure is higher because of hypotension, peripheral edema, and obesity. Ultrasound guidance significantly increases the likelihood of successful cannulation and decreases complications compared with traditional landmark-based techniques. Multiple ultrasound techniques for radial and femoral arterial catheter insertion have been described; this paper presents an approach for incorporating these tools into bedside practice, including illustrative figures and narrated video presentations to demonstrate the techniques described. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
29. Managing Massive Hemoptysis.
- Author
-
Davidson, Kevin and Shojaee, Samira
- Subjects
- *
HEMOPTYSIS , *BRONCHIAL arteries , *BRONCHOSCOPY , *MEDICAL emergencies , *THERAPEUTIC embolization , *HEMORRHAGE , *ETIOLOGY of diseases , *FIBRINOLYTIC agents , *ELECTROCOAGULATION (Medicine) , *DIFFERENTIAL diagnosis , *PROGNOSIS , *IATROGENIC diseases , *DIAGNOSTIC imaging , *TRACHEA intubation - Abstract
Massive hemoptysis is a medical emergency with high mortality presenting several difficult diagnostic and therapeutic challenges. The origin of bleeding and underlying etiology often is not immediately apparent, and techniques for management of this dangerous condition necessitate an expedient response. Unlike hemorrhage in other circumstances, a small amount of blood can rapidly flood the airways, thereby impairing oxygenation and ventilation, leading to asphyxia and consequent cardiovascular collapse. Of paramount importance is early control of the patient's airway and immediate isolation of hemorrhage in an attempt to localize and control bleeding. A coordinated team response is essential to guarantee the best chances of patient survival. Prompt control of the airway and steps to limit the spread of hemorrhage take precedence. Bronchial artery embolization, rigid and flexible bronchoscopy, and surgery all serve as potential treatment options to provide definitive control of hemorrhage. Several adjunctive therapies described in recent years may also assist in the control of bleeding; however, their role is less defined in life-threatening hemoptysis and warrants additional studies. In this concise review, we emphasize the steps necessary for a systematic approach in the management of life-threatening hemoptysis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
30. CLINICAL DECISION SUPPORT SYSTEMS TO RULE OUT INTRACRANIAL BLEEDING AFTER IN-PATIENT BLUNT HEAD TRAUMA: A VALIDATION STUDY.
- Author
-
ALWAKEEL, MAHMOUD, SHAHEEN, HASSAN, KARKI, ARPAN, AFZAL, SAIRA, ALAYAN, DINA, TAUQUIR, ANOOSHA, OBEIDAT, MOHAMMED, WANG, XIAOFENG, and AL-JAGHBEER, MOHAMMED
- Subjects
- *
CLINICAL decision support systems , *BLUNT trauma , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
31. PERSISTENT CEREBRAL VENOUS SINUS THROMBOSIS COMPLICATED BY SUBDURAL HEMORRHAGE.
- Author
-
SIVA, AJAY, TAYLOR, AARON, and MAGUN, RICK
- Subjects
- *
SINUS thrombosis , *CRANIAL sinuses , *VENOUS thrombosis , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
32. BALANCE BETWEEN THROMBOSIS AND MAJOR BLEEDING EVENTS IN A SPECIFIC SUBSET OF PATIENTS WITH OUT OF HOSPITAL CARDIAC ARREST (OHCA): A CASE REPORT.
- Author
-
ROHIT MEKALA, SAI and PAVAN K KOTARU, VEERA
- Subjects
- *
CARDIAC arrest , *HOSPITAL patients , *HEMORRHAGE , *THROMBOSIS - Published
- 2023
- Full Text
- View/download PDF
33. INHALED ANESTHETIC-INDUCED DIFFUSE ALVEOLAR HEMORRHAGE.
- Author
-
AZEEM, AHAD and STALLER, ALEXANDER R
- Subjects
- *
HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
34. Where Does Tranexamic Acid Fit in the Armamentarium for Bronchoscopic Bleeding?
- Author
-
Revelo, Alberto E. and Pastis, Nicholas J.
- Subjects
- *
HEMORRHAGE , *TRANEXAMIC acid - Published
- 2023
- Full Text
- View/download PDF
35. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation.
- Author
-
Chan, Yi-Hsin, Lee, Hsin-Fu, See, Lai-Chu, Tu, Hui-Tzu, Chao, Tze-Fan, Yeh, Yung-Hsin, Wu, Lung-Sheng, Kuo, Chi-Tai, Chang, Shang-Hung, and Lip, Gregory Y.H.
- Subjects
- *
ATRIAL fibrillation , *TRANSIENT ischemic attack , *NATIONAL health insurance , *CONGESTIVE heart failure , *VASCULAR diseases , *WARFARIN , *PYRIDINE , *DATABASES , *RESEARCH , *STROKE , *HETEROCYCLIC compounds , *ORAL drug administration , *RESEARCH methodology , *ANTICOAGULANTS , *RETROSPECTIVE studies , *EVALUATION research , *MEDICAL cooperation , *TREATMENT effectiveness , *COMPARATIVE studies , *THROMBOEMBOLISM , *HEMORRHAGE , *THIAZOLES , *DISEASE complications - Abstract
Background: Whether four direct oral anticoagulants (DOACs) are superior to warfarin in Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear.Methods: This nationwide retrospective cohort study was based on data from Taiwan's National Health Insurance Research Database from June 1, 2012, to December 31, 2017, covering patients with NVAF taking edoxaban (n = 4,577), apixaban (n = 9,952), rivaroxaban (n = 33,022), dabigatran (n = 22,371), and warfarin (n = 19,761). Propensity score weighting was used to balance covariates across study groups. Patients were followed up until occurrence of study outcomes or end date of study.Results: Edoxaban, apixaban, and rivaroxaban were associated with a lower risk of ischemic stroke/systemic embolism than warfarin. All DOACs had a lower risk of major bleeding than warfarin. Apixaban was associated with a lower risk of major bleeding than rivaroxaban and dabigatran, whereas the risk of major bleeding was comparable between edoxaban and apixaban. The reduced risks of thromboembolism/major bleeding for the four DOACs persisted in high-risk subgroups, including those with chronic kidney disease, elderly patients (age ≥ 75 years), secondary stroke prevention, or CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65-74 years, and female sex) ≥ 4. A total of 2,924 (64%), 6,359 (64%), 31,108 (94%), and 19,821 (89%) patients received low-dose edoxaban (15-30 mg/d), apixaban (2.5 mg bid), rivaroxaban (10-15 mg/d), and dabigatran (110 mg bid), respectively. The effectiveness/safety outcomes with the four low-dose DOACs compared with warfarin were consistent with the main analysis.Conclusions: In the largest real-world practice study among Asian patients with NVAF, four DOACs were associated with a comparable or lower risk of thromboembolism, and a lower risk of bleeding than warfarin. There was consistency even among high-risk subgroups and whether standard-or low-dose regimens were compared. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
36. Inhaled Tranexamic Acid for Hemoptysis Treatment: A Randomized Controlled Trial.
- Author
-
Wand, Ori, Guber, Elad, Guber, Alexander, Epstein Shochet, Gali, Israeli-Shani, Lilach, and Shitrit, David
- Subjects
- *
TRANEXAMIC acid , *HEMORRHAGE , *FIBRINOLYSIS , *HEMOPTYSIS , *BLOOD volume - Abstract
Background: Tranexamic acid (TA) is an antifibrinolytic drug currently used systemically to control bleeding. To date, there have been no prospective studies of the effectiveness of inhaled TA for the treatment of hemoptysis.Objectives: The goal of this study was to prospectively assess the effectiveness of TA inhalations (ie, nebulized TA) for hemoptysis treatment.Methods: This analysis was a double-blind, randomized controlled trial of treatment with nebulized TA (500 mg tid) vs placebo (normal saline) in patients admitted with hemoptysis of various etiologies. Patients with massive hemoptysis (expectorated blood > 200 mL/24 h) and hemodynamic or respiratory instability were excluded. Mortality and hemoptysis recurrence rate were assessed at 30 days and following 1 year.Results: Forty-seven patients were randomized to receive TA inhalations (n = 25) or normal saline (n = 22). TA was associated with a significantly reduced expectorated blood volume starting from day 2 of admission. Resolution of hemoptysis within 5 days of admission was observed in more TA-treated patients than in those receiving placebo (96% vs 50%; P < .0005). Mean hospital length of stay was shorter for the TA group (5.7 ± 2.5 days vs 7.8 ± 4.6 days; P = .046), with fewer patients requiring invasive procedures such as interventional bronchoscopy or angiographic embolization to control the bleeding (0% vs 18.2%; P = .041). No side effects were noted in either group throughout the follow-up period. In addition, a reduced recurrence rate was noted at the 1-year follow-up (P = .009).Conclusions: TA inhalations can be used safely and effectively to control bleeding in patients with nonmassive hemoptysis.Trial Registry: ClinicalTrials.gov; No.: NCT01496196; URL: www.clinicaltrials.gov. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
37. Time to Use Direct Oral Anticoagulants to Prevent Recurrences and Major Acute Cardiovascular Events After VTE?
- Author
-
Becattini, Cecilia and Vedovati, Maria Cristina
- Subjects
- *
ORAL medication , *TIME management , *VEINS , *ORAL drug administration , *ANTICOAGULANTS , *DISEASE relapse , *THROMBOEMBOLISM , *HEMORRHAGE ,THROMBOEMBOLISM prevention - Published
- 2022
- Full Text
- View/download PDF
38. A RARE CASE OF ANTINEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-NEGATIVE PAUCI- IMMUNE FOCAL NECROTIZING AND CRESCENTIC GLOMERULONEPHRITIS PRESENTING WITH DIFFUSE ALVEOLAR HEMORRHAGE.
- Author
-
QADRI, ANUM N, S COOLIDGE, BRADLEY, SARGUROH, TAUSEEF, and E GERINGER, CHARLES
- Subjects
- *
ANTINEUTROPHIL cytoplasmic antibodies , *GLOMERULONEPHRITIS , *HEMORRHAGE , *PULMONARY alveolar proteinosis - Published
- 2022
- Full Text
- View/download PDF
39. A RARE CASE OF DIFFUSE ALVEOLAR HEMORRHAGE SECONDARY TO HYDRALAZINE-INDUCED LUPUS.
- Author
-
SHAH, PARTH, K PANDYA, KRUTARTH, PATEL, JANKI, N ANTALA, DRASHTI, SAHA, PRATIK, and BOULOS, ANTHONY
- Subjects
- *
HEMORRHAGE , *PULMONARY alveolar proteinosis - Published
- 2022
- Full Text
- View/download PDF
40. MALIGNANT GLOMUS TUMOR WITH UNSTABLE HEMORRHAGE.
- Author
-
BRADSHAW, DEVIN, J DICHIARA, GERARD, HARLEY, DUSHAWN, TELLIARD, JOSEPH, OGUREK, IAN, YEGUDKIN, ILYA, AKBARULLAH, SYED, B SCHNEIDER, XENIA, DEL MUNDO, LLOYD, HRUSKA, JEROME, and A STEWART, PAUL
- Subjects
- *
HEMORRHAGE , *TUMORS - Published
- 2022
- Full Text
- View/download PDF
41. POTENTIAL NEW INDICATION FOR TRANEXAMIC ACID: END-STAGE LIVER DISEASE WITH REFRACTORY BLEEDING.
- Author
-
ABDELHABIB, MOHAMED, BENSON, ALICIA, J TAYLOR, CHRIS, MORRISON, ZACHARY, and CRAWFORD, JULIE
- Subjects
- *
LIVER diseases , *HEMORRHAGE , *TRANEXAMIC acid - Published
- 2022
- Full Text
- View/download PDF
42. DIFFUSE ALVEOLAR HEMORRHAGE SECONDARY TO IMMUNE THROMBOCYTOPENIA FOLLOWING SARS-COV-2 VACCINATION: A CASE REPORT.
- Author
-
CHENG, TIEWEI, HUANG, JIN, KHALID, SANAULLAH, G. EL AMIL, ZEINA, and J BARREIRO, TIMOTHY
- Subjects
- *
IDIOPATHIC thrombocytopenic purpura , *SARS-CoV-2 , *HEMORRHAGE , *VACCINATION - Published
- 2022
- Full Text
- View/download PDF
43. A RARE CASE OF MASSIVE RENAL VEIN HEMORRHAGE IN TRANSPLANT FOR LUPUS NEPHRITIS END-STAGE RENAL DISEASE.
- Author
-
CHAO, CHEN, ADAM, ADAM, BACHAN, MOSES, and KHAN, ZINOBIA
- Subjects
- *
CHRONIC kidney failure , *RENAL veins , *LUPUS nephritis , *HEMORRHAGE - Published
- 2022
- Full Text
- View/download PDF
44. Preemptive Anticoagulation in Patients With a High Pretest Probability of Pulmonary Embolism: Are Guidelines Followed?
- Author
-
Willoughby, Laura, Adams, Daniel M., Evans, R. Scott, Lloyd, James F., Stevens, Scott M., Woller, Scott C., Bledsoe, Joseph R., Aston, Valerie T., Wilson, Emily L., and Elliott, C. Gregory
- Subjects
- *
PULMONARY embolism , *ANGIOGRAPHY , *HEPARIN , *BLOOD coagulation , *COMPUTED tomography , *HEMORRHAGE , *PATIENTS - Abstract
Background: Guidelines suggest anticoagulation of patients with high pretest probability of pulmonary embolism (PE) while awaiting diagnostic test results (preemptive anticoagulation). Data relevant to the practice of preemptive anticoagulation are not available.Methods: We reviewed 3,500 consecutive patients who underwent CT pulmonary angiography (CTPA) at two EDs. We classified the pretest probability for PE using the revised Geneva Score (RGS) as low (RGS 0-3), intermediate (RGS 4-10), or high (RGS 11-18). We classified patients with a high pretest probability of PE as receiving preemptive anticoagulation if therapeutic anticoagulation was given before CTPA completion. Patients with a high bleeding risk and those receiving treatment for DVT before CTPA were excluded from the preemptive anticoagulation analysis. We compared the time elapsed between ED registration and CTPA completion for patients with a low, intermediate, and high pretest probability for PE.Results: We excluded three of 3,500 patients because CTPA preceded ED registration. Of the remaining 3,497 patients, 167 (4.8%) had a high pretest probability for PE. After excluding 29 patients for high bleeding risk and 21 patients who were treated for DVT prior to CTPA, only two of 117 patients (1.7%) with a high pretest probability for PE received preemptive anticoagulation. Furthermore, 37 of the remaining 115 patients (32%) with a high pretest probability for PE had a preexisting indication for anticoagulation but did not receive preemptive anticoagulation. The time from ED registration to CTPA completion did not differ based on the pretest probability of PE.Conclusions: Physicians rarely use preemptive anticoagulation in patients with a high pretest probability for PE. Clinicians do not expedite CTPA examinations for patients with a high pretest probability for PE. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
45. Histopathologic Findings in Lungs of Patients Treated With Extracorporeal Membrane Oxygenation.
- Author
-
Lee, Hee Eun, Yi, Eunhee S., Rabatin, Jeffrey T., Bohman, J. Kyle, and Roden, Anja C.
- Subjects
- *
EXTRACORPOREAL membrane oxygenation , *LUNG diseases , *LUNG injuries , *AUTOPSY , *ADULT respiratory distress syndrome , *HEMORRHAGE , *PULMONARY hypertension , *REGRESSION analysis , *THROMBOEMBOLISM , *MECHANICAL ventilators , *CASE-control method , *ACUTE diseases - Abstract
Background: The outcome of extracorporeal membrane oxygenation (ECMO) might be influenced by its complications. Only limited information is available regarding the pathologic consequences of ECMO, especially in the era of modern ECMO technology.Methods: We studied the histopathologic findings in autopsy lungs of patients treated with ECMO compared with those without ECMO. Autopsy files were queried for cases with ECMO. An age- and sex-matched control group comprised of patients who died in the ICU without acute respiratory distress syndrome, pneumonia, or ECMO was compared with patients with ECMO for cardiac reason. Histopathology and medical records were reviewed.Results: Seventy-six patients treated with ECMO (38 men; median age, 40 years) and 47 control patients (23 men; median age, 45 years) were included. Common histologic pulmonary findings in the ECMO group were pulmonary hemorrhage (63.2%), acute lung injury (60.5%), thromboembolic disease (47.4%), calcifications (28.9%), vascular changes (21.1%), and hemorrhagic infarct (21.1%). Pulmonary hemorrhage was associated with longer ECMO duration (median, 7.0 vs 3.5 months; P = .014), acute lung injury with venovenous ECMO (91.7% vs 54.7%; P = .039) and longer ECMO (6.0 vs 4.0 months; P = .044), and pulmonary calcifications with infants (50.0% vs 22.4%; P = .024). Patients with ECMO for cardiac reasons (n = 60) more frequently showed pulmonary hemorrhage (P < .001), diffuse alveolar damage (P = .044), thromboembolic disease (P = .004), hemorrhagic infarct (P = .002), pulmonary calcifications (P = .002), and vascular changes (P = .001) than patients in the non-ECMO group.Conclusions: Some findings are suspected to be associated with the patient's underlying disease, whereas others might be related to ECMO. Our results provide a better understanding of ECMO-related lung disease and might help to prevent it. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
46. A Closer Look Into a Bleeding Lung...
- Author
-
Mahendran, A.J. and Gupta, Nitesh
- Subjects
- *
LUNGS , *HEMORRHAGE - Published
- 2023
- Full Text
- View/download PDF
47. Bleeding Risk With Combination Intrapleural Fibrinolytic and Enzyme Therapy in Pleural Infection: An International, Multicenter, Retrospective Cohort Study
- Author
-
Jason, Akulian, Eihab O, Bedawi, Hawazin, Abbas, Christine, Argento, David T, Arnold, Akshu, Balwan, Hitesh, Batra, Juan Pablo, Uribe Becerra, Adam, Belanger, Kristin, Berger, Allen Cole, Burks, Jiwoon, Chang, Ara A, Chrissian, David M, DiBardino, Xavier Fonseca, Fuentes, Yaron B, Gesthalter, Christopher R, Gilbert, Kristen, Glisinski, Mark, Godfrey, Jed A, Gorden, Horiana, Grosu, Mridul, Gupta, Fayez, Kheir, Kevin C, Ma, Adnan, Majid, Fabien, Maldonado, Nick A, Maskell, Hiren, Mehta, Joshua, Mercer, John, Mullon, Darlene, Nelson, Elaine, Nguyen, Edward M, Pickering, Jonathan, Puchalski, Chakravarthy, Reddy, Alberto E, Revelo, Lance, Roller, Ashutosh, Sachdeva, Trinidad, Sanchez, Priya, Sathyanarayan, Roy, Semaan, Michal, Senitko, Samira, Shojaee, Ryan, Story, Jeffrey, Thiboutot, Momen, Wahidi, Candice L, Wilshire, Diana, Yu, Aline, Zouk, Najib M, Rahman, and Lonny, Yarmus
- Subjects
Pleural Effusion ,Fibrinolytic Agents ,Tissue Plasminogen Activator ,Humans ,Enzyme Therapy ,Hemorrhage ,Pleural Diseases ,Communicable Diseases ,Empyema, Pleural ,Retrospective Studies - Abstract
Combination intrapleural fibrinolytic and enzyme therapy (IET) has been established as a therapeutic option in pleural infection. Despite demonstrated efficacy, studies specifically designed and adequately powered to address complications are sparse. The safety profile, the effects of concurrent therapeutic anticoagulation, and the nature and extent of nonbleeding complications remain poorly defined.What is the bleeding complication risk associated with IET use in pleural infection?This was a multicenter, retrospective observational study conducted in 24 centers across the United States and the United Kingdom. Protocolized data collection for 1,851 patients treated with at least one dose of combination IET for pleural infection between January 2012 and May 2019 was undertaken. The primary outcome was the overall incidence of pleural bleeding defined using pre hoc criteria.Overall, pleural bleeding occurred in 76 of 1,833 patients (4.1%; 95% CI, 3.0%-5.0%). Using a half-dose regimen (tissue plasminogen activator, 5 mg) did not change this risk significantly (6/172 [3.5%]; P = .68). Therapeutic anticoagulation alongside IET was associated with increased bleeding rates (19/197 [9.6%]) compared with temporarily withholding anticoagulation before administration of IET (3/118 [2.6%]; P = .017). As well as systemic anticoagulation, increasing RAPID score, elevated serum urea, and platelets of 100 × 10IET use in pleural infection confers a low overall bleeding risk. Increased rates of pleural bleeding are associated with concurrent use of anticoagulation but can be mitigated by withholding anticoagulation before IET. Concomitant administration of IET and therapeutic anticoagulation should be avoided. Parameters related to higher IET-related bleeding have been identified that may lead to altered risk thresholds for treatment.
- Published
- 2022
48. Direct Oral Anticoagulant- or Warfarin-Related Major Bleeding: Characteristics, Reversal Strategies, and Outcomes From a Multicenter Observational Study.
- Author
-
Xu, Yan, Schulman, Sam, Dowlatshahi, Dar, Holbrook, Anne M., Simpson, Christopher S., Shepherd, Lois E., Wells, Philip S., Giulivi, Antonio, Gomes, Tara, Mamdani, Muhammad, Khuu, Wayne, Frymire, Eliot, Johnson, Ana P., and Bleeding Effected by Direct Oral Anticoagulants (BLED-AC) Study Group
- Subjects
- *
HEMORRHAGE , *ANTICOAGULANTS , *WARFARIN , *RED blood cell transfusion , *VITAMIN K , *PROTHROMBIN , *HEMORRHAGE diagnosis , *HEMORRHAGE treatment , *PROTEOLYTIC enzymes , *RECOMBINANT proteins , *BLOOD coagulation factors , *STROKE prevention , *ATRIAL fibrillation , *COMPARATIVE studies , *RESEARCH methodology , *MEDICAL cooperation , *PROTEINS , *RESEARCH , *STROKE , *EVALUATION research , *RETROSPECTIVE studies , *HOSPITAL mortality , *DISEASE complications , *THERAPEUTICS - Abstract
Background: Direct oral anticoagulants (DOACs) have expanded the armamentarium for antithrombotic therapy. Although DOAC-related major bleeding was associated with favorable outcomes compared with warfarin in clinical trials, warfarin effects were reversed in < 40% of cases, raising concerns about the generalizability of this finding.Methods: Consecutive patients ≥ 66 years presented to five tertiary care hospitals across three cities in Ontario, Canada from October 2010 to March 2015 with diagnoses that included hemorrhage. Charts were screened for association with DOAC or warfarin use; eligible cases were abstracted and linked to administrative databases.Results: Among 19,061 records screened, 2,002 (460 receiving DOAC, 1,542 receiving warfarin) were eligible. Reversal agents (72.9% vitamin K, 40.7% prothrombin complex concentrates) were frequently used in warfarin bleeding events. Red blood cell transfusions occurred more often in DOAC bleeding events than in warfarin events (52.0% vs 39.5%; adjusted relative risk [aRR], 1.32; 95% CI, 1.19-2.47). However, units of blood products transfused were not different between the two groups. Thirty-four DOAC cases (7.4%) received activated prothrombin complex concentrates or recombinant factor VIIa. In-hospital mortality was lower following DOAC bleeding events (9.8% vs 15.2%; aRR, 0.66; 95% CI, 0.49-0.89), although differences in 30-day mortality did not reach statistical significance (12.6% vs 16.3%; aRR, 0.79; 95% CI, 0.61-1.03).Conclusions: In this unselected cohort of patients with oral anticoagulant-related hemorrhage with high rates of warfarin reversal, in-hospital mortality was lower among DOAC-associated bleeding events. These findings support the safety of DOACs in routine care and present useful baseline measures for evaluations of DOAC-specific reversal agents. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
49. Chest CT Signs in Pulmonary Disease: A Pictorial Review.
- Author
-
Raju, Shine, Ghosh, Subha, and Mehta, Atul C.
- Subjects
- *
LUNG diseases , *PULMONOLOGISTS , *VASCULAR diseases , *RADIOGRAPHS , *DISEASES , *ADENOCARCINOMA , *SARCOIDOSIS , *LUNGS , *PNEUMOCYSTIS pneumonia , *MULTIDETECTOR computed tomography , *HYPERSENSITIVITY pneumonitis , *LUNG tumors , *GENETIC disorders , *PULMONARY alveolar proteinosis , *CYSTIC fibrosis , *PULMONARY aspergillosis , *CALCINOSIS , *PLEURA diseases , *EMPYEMA , *COMPUTED tomography , *ATELECTASIS , *MYCOBACTERIAL diseases , *LYMPHOMAS , *FOREIGN bodies , *SQUAMOUS cell carcinoma , *HEMORRHAGE - Abstract
CT scanning of the chest is one of the most important imaging modalities available to a pulmonologist. The advent of high-resolution CT scanning of the chest has led to its increasing use. Although chest radiographs are still useful as an initial test, their utility is limited in the diagnosis of lung diseases that depend on higher resolution images such as interstitial lung diseases and pulmonary vascular diseases. Several metaphoric chest CT scan signs have been described linking abnormal imaging patterns to lung diseases. Some of these are specific to a disease, whereas others help narrow the differential diagnosis. Recognizing these imaging patterns and CT scan signs are thus vitally important. In the present article, we describe a comprehensive list of the commonly encountered metaphoric chest CT scan signs and their clinical relevance. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
50. Initial Anticoagulant Treatment of Pulmonary Embolism: How Can We Better Predict Bleeding in the Early Days Rather Than the Early Months?
- Author
-
Laurent, Bertoletti
- Subjects
Anticoagulants ,Humans ,Hemorrhage ,Pulmonary Embolism - Published
- 2021
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.